EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Validierungsstudie

Pharmacokinetic and pharmacodynamic modelling of continuous erythropoiesis receptor activator in children: A comprehensive analysis and real‐world data validation

Samer Mouksassi, Franz Schaefer, Bradley A Warady, Claus P Schmitt, Sylvie Meyer Reigner, Milena Studer, Pascal Chanu iD, Nicolas Frey iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70165 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Samer Mouksassi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Certara, Cairo, Egypt. Hauptthemen laut MEDLINE: Models, Biological, Renal Insufficiency, Chronic, Polyethylene Glycols, Erythropoietin. Die Arbeit nennt 18 Literaturangaben. Gefördert von: F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To further assess the pharmacokinetic/pharmacodynamic characteristics of methoxy polyethylene glycol‐epoetin β (continuous erythropoiesis receptor activator; C.E.R.A.) in children with chronic kidney disease (CKD) aged 3 months to 18 years undergoing different dialysis modalities and receiving intravenous/subcutaneous doses, compared with adults.

Methods

The population pharmacokinetic and pharmacokinetic/pharmacodynamic C.E.R.A. models, developed using intravenous and subcutaneous data from adults with various dialysis modalities and intravenous data from children receiving haemodialysis, were updated with subcutaneous data from children receiving peritoneal dialysis or predialysis from the phase II paediatric study NH19708 (SKIPPER). Observed and predicted median C.E.R.A. doses and mean haemoglobin levels (indicative of response) were compared using paediatric clinical trials and real‐world data from the MH40258 registry study.

Results

The pharmacokinetic analysis in 627 patients, including 103 children aged 0.5–17 years, revealed that subcutaneous bioavailability in children was 2.18 times higher than in adults (67.1% [95% confidence interval: 52.6–81.6]). Distribution volume increased with weight and age, and clearance increased with weight. Incorporating dialysis modality as a covariate improved the pharmacokinetic/pharmacodynamic model's fit to haemoglobin data. The agreement of observed and predicted paediatric data with real‐world data underscores the model's predictive performance and C.E.R.A.’s replicable clinical trial effects in clinical practice.

Conclusions

This analysis enhanced our knowledge of C.E.R.A.’s effects in children with CKD, confirming its pharmacokinetic/pharmacodynamic characteristics align with adults. Comparison of clinical trial data, model prediction, and real‐world data show that C.E.R.A. intravenous and subcutaneous dosing and procedures in adults and children provide adequate control of haemoglobin in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalRenal Insufficiency, ChronicPolyethylene GlycolsErythropoietinHematinicsAnemiaHumansChildAdolescentChild, PreschoolInfantMaleFemaleHemoglobinsRenal DialysisBiological AvailabilityAdultInjections, SubcutaneousAge Factors

Stichwörter der Autor:innen

anaemiachronic kidney diseasepaediatricspharmacodynamicspharmacokinetics

Substanzen

continuous erythropoietin receptor activatorPolyethylene GlycolsErythropoietinHemoglobinsHematinics

Autor:innen und Institutionen

  • Certara, Cairo, Egypt.
  • Medical Faculty Heidelberg, Centre for Pediatric and Adolescent Medicine, Clinic 1, Pediatric Nephrology, Heidelberg University, Heidelberg, Germany.
  • Children's Mercy Kansas City, University of Missouri - Kansas City, MO, USA.
  • F.Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Clinical Pharmacology, Genentech/Roche, Lyon, France.
  • Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.

ORCID-Profile: Pascal Chanu, Nicolas Frey

Förderung

  • F. Hoffmann-La Roche

Zitieren

APA

Mouksassi, S., Schaefer, F., Warady, B. A., Schmitt, C. P., Reigner, S. M., Studer, M., Chanu, P., & Frey, N. (2025). Pharmacokinetic and pharmacodynamic modelling of continuous erythropoiesis receptor activator in children: A comprehensive analysis and real‐world data validation. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70165

Vancouver

Mouksassi S, Schaefer F, Warady BA, Schmitt CP, Reigner SM, Studer M, et al. Pharmacokinetic and pharmacodynamic modelling of continuous erythropoiesis receptor activator in children: A comprehensive analysis and real‐world data validation. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70165

BibTeX
@article{Mouksassi2025,
  author = {Mouksassi, Samer and Schaefer, Franz and Warady, Bradley A and Schmitt, Claus P and Reigner, Sylvie Meyer and Studer, Milena and Chanu, Pascal and Frey, Nicolas},
  title = {Pharmacokinetic and pharmacodynamic modelling of continuous erythropoiesis receptor activator in children: A comprehensive analysis and real‐world data validation},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70165}
}
Kostenlos starten →